Brief: Pds Biotech Announces Interim Safety And Immune Response Data From Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate Pds0301 Combined With Docetaxel To Treat Metastatic Prostate Cancer
11/10/2023 13:05
Oct 11 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH ANNOUNCES INTERIM SAFETY AND IMMUNE RESPONSE
DATA
FROM PHASE 1/2 CLINICAL TRIAL EVALUATING NOVEL ANTIBODY DRUG
CONJUGATE PDS0301 COMBINED WITH DOCETAXEL TO TREAT METASTATIC
PROSTATE CANCER
* PDS BIOTECHNOLOGY CORP: COMBINATION WAS WELL-TOLERATED AT
ALL
TESTED DOSE LEVELS.
* PDS BIOTECHNOLOGY CORP: DECREASE IN PROSTATE SPECIFIC
ANTIGEN
LEVELS WAS SEEN IN ALL PATIENTS AT ALL THREE TESTED DOSES OF
PDS0301
Source text for Eikon: ID:nGNX7LLp3X
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing